Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Zymeworks in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.59) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.75) EPS and FY2027 earnings at ($1.58) EPS.

Several other research analysts also recently weighed in on ZYME. Wells Fargo & Company boosted their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Citigroup upped their price objective on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Leerink Partners upgraded Zymeworks from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $10.00 to $25.00 in a report on Thursday, November 7th. Finally, Stifel Nicolaus upped their price target on shares of Zymeworks from $21.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Zymeworks has an average rating of “Moderate Buy” and a consensus target price of $19.17.

Zymeworks Price Performance

Shares of NYSE:ZYME opened at $14.19 on Monday. The business’s 50 day simple moving average is $14.12 and its 200-day simple moving average is $13.20. The firm has a market capitalization of $977.38 million, a price-to-earnings ratio of -9.46 and a beta of 1.10. Zymeworks has a 12 month low of $7.97 and a 12 month high of $17.70.

Institutional Investors Weigh In On Zymeworks

A number of hedge funds have recently made changes to their positions in ZYME. AlphaQuest LLC increased its stake in shares of Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after acquiring an additional 2,324 shares during the period. FMR LLC increased its stake in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Zymeworks during the third quarter valued at approximately $47,000. nVerses Capital LLC acquired a new position in shares of Zymeworks during the third quarter valued at approximately $79,000. Finally, New York State Common Retirement Fund increased its stake in shares of Zymeworks by 42.7% during the fourth quarter. New York State Common Retirement Fund now owns 13,371 shares of the company’s stock valued at $196,000 after acquiring an additional 4,000 shares during the period. Institutional investors own 92.89% of the company’s stock.

Insider Activity

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 16,692 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were bought at an average price of $14.38 per share, with a total value of $240,030.96. Following the completion of the acquisition, the director now owns 14,720,931 shares in the company, valued at approximately $211,686,987.78. This represents a 0.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul Andrew Moore sold 21,200 shares of Zymeworks stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $14.92, for a total value of $316,304.00. Following the sale, the insider now directly owns 14,741 shares in the company, valued at approximately $219,935.72. This trade represents a 58.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 603,539 shares of company stock worth $8,384,708 and have sold 89,601 shares worth $1,336,847. Company insiders own 1.92% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.